Drugmakers ring in the new year with higher drug prices
On Tuesday, more than three dozen pharmaceutical companies raised prices on hundreds of drugs in the U.S., and Allergan led the way, raising prices on 27 medicines by just under 10 percent, The Wall Street Journal reports, citing an analysis from Rx Savings Solutions. The average increase in drug list prices was 6.3 percent, and both brand-name drugmakers like Allergan and generics makers like Hikma Pharmaceuticals raised prices well above inflation. Allergan raised prices on about half its drugs, including the Alzheimer's medication Namenda, and Hikma increased prices for morphine, the anesthetic ketamine, and enalaprilat, a drug-pressure drug, the Journal notes.
There is increasing political pressure to tamp down pharmaceutical price hikes, but "the reason it can keep happening is there is no market check, no person or entity to bring reason to determining drug prices," said Michael Rea, CEO of Rx Savings Solutions, which sells software to companies and health plans to help them find the cheapest medicines.
House Democrats are expected to put pressure on drugmakers this year, and the Trump administration has proposed making pharmaceutical companies state their list prices in TV ads. Pfizer announced that it was freezing drug price increases over the summer in response to pressure from the Trump administration, but it will go back to raising prices on 41 of its drugs later this month, the Journal notes.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Reddit IPO values social media site at $6.4 billion
Speed Read The company makes its public debut on the New York Stock Exchange
By Peter Weber, The Week US Published
-
Housing costs: the root of US economic malaise?
speed read Many voters are troubled by the housing affordability crisis
By Peter Weber, The Week US Published
-
Feds cap credit card late fees at $8
speed read The Consumer Financial Protection Bureau finalized a rule to save households an estimated $10 billion a year
By Peter Weber, The Week US Published
-
Immigration helped the US economy outpace peers
speed read The U.S. economy grew at an annualized rate of 3.2% last quarter
By Peter Weber, The Week US Published
-
4-day workweek gets boost from UK study
Speed Read Following a six-month trial, the majority of participating British companies are still using the truncated schedule
By Peter Weber, The Week US Published
-
US sues to block Kroger-Albertsons merger
Speed Read The Federal Trade Commission sued to block the $24.6 billion merger between the grocery giants
By Peter Weber, The Week US Published
-
Nvidia sees historic stock rise on AI chips success
Speed Read U.S. chipmaker Nvidia achieved the biggest one-day increase in value of any company in history
By Peter Weber, The Week US Published
-
New York may seize Trump's assets for $450M penalty
Speed Read The former president likely owes $600 million from two civil judgments in New York
By Peter Weber, The Week US Published